Record Information |
---|
Version | 1.0 |
---|
Creation Date | 2016-05-25 18:09:36 UTC |
---|
Update Date | 2016-11-09 01:17:20 UTC |
---|
Accession Number | CHEM021670 |
---|
Identification |
---|
Common Name | 6-Keto-prostaglandin F1a |
---|
Class | Small Molecule |
---|
Description | A prostaglandin Falpha that is prostaglandin F1alpha bearing a keto substituent at the 6-position. |
---|
Contaminant Sources | - FooDB Chemicals
- HMDB Contaminants - Urine
|
---|
Contaminant Type | Not Available |
---|
Chemical Structure | |
---|
Synonyms | Value | Source |
---|
6-Keto-PGF1a | ChEBI | 6-Keto-PGF1alpha | ChEBI | 6-Keto-prostaglandin F1alpha | ChEBI | 6-Ketoprostaglandin F1alpha | ChEBI | 6-oxo-PGF1alpha | ChEBI | 6-oxo-Prostaglandin F1alpha | ChEBI | 6-Keto-PGF1α | Generator | 6-Keto-prostaglandin F1α | Generator | 6-Ketoprostaglandin F1a | Generator | 6-Ketoprostaglandin F1α | Generator | 6-oxo-PGF1a | Generator | 6-oxo-PGF1Α | Generator | 6-oxo-Prostaglandin F1a | Generator | 6-oxo-Prostaglandin F1α | Generator | 6 oxo PGF1 alpha | MeSH | 6 Oxoprostaglandin F1 alpha | MeSH | 6-Keto-PGF1 alpha | MeSH | 6-oxo-PGF1 alpha | MeSH | F1 alpha, 6-Oxoprostaglandin | MeSH | alpha, 6-Keto-PGF1 | MeSH | alpha, 6-Oxoprostaglandin F1 | MeSH | 6 Keto PGF1 alpha | MeSH | 6-Ketoprostaglandin F1 alpha | MeSH | 6-Oxoprostaglandin F1 alpha | MeSH | F1 alpha, 6-Ketoprostaglandin | MeSH | alpha, 6-Ketoprostaglandin F1 | MeSH | alpha, 6-oxo-PGF1 | MeSH | 6 Ketoprostaglandin F1 alpha | MeSH | 6-Oxoprostaglandin F1alpha | ChEBI, HMDB | 6-Oxoprostaglandin F1a | Generator, HMDB | 6-Oxoprostaglandin F1α | Generator, HMDB | 6-oxo-9S,11R,15S-Trihydroxy-13E-prostenoate | HMDB | 6-oxo-9S,11R,15S-Trihydroxy-13E-prostenoic acid | HMDB |
|
---|
Chemical Formula | C20H34O6 |
---|
Average Molecular Mass | 370.480 g/mol |
---|
Monoisotopic Mass | 370.236 g/mol |
---|
CAS Registry Number | 58962-34-8 |
---|
IUPAC Name | 7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(1E,3S)-3-hydroxyoct-1-en-1-yl]cyclopentyl]-6-oxoheptanoic acid |
---|
Traditional Name | 6 keto PGF1 α |
---|
SMILES | CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)C[C@H](O)[C@@H]1CC(=O)CCCCC(O)=O |
---|
InChI Identifier | InChI=1S/C20H34O6/c1-2-3-4-7-14(21)10-11-16-17(19(24)13-18(16)23)12-15(22)8-5-6-9-20(25)26/h10-11,14,16-19,21,23-24H,2-9,12-13H2,1H3,(H,25,26)/b11-10+/t14-,16+,17+,18+,19-/m0/s1 |
---|
InChI Key | KFGOFTHODYBSGM-ZUNNJUQCSA-N |
---|
Chemical Taxonomy |
---|
Description | belongs to the class of organic compounds known as prostaglandins and related compounds. These are unsaturated carboxylic acids consisting of a 20 carbon skeleton that also contains a five member ring, and are based upon the fatty acid arachidonic acid. |
---|
Kingdom | Organic compounds |
---|
Super Class | Lipids and lipid-like molecules |
---|
Class | Fatty Acyls |
---|
Sub Class | Eicosanoids |
---|
Direct Parent | Prostaglandins and related compounds |
---|
Alternative Parents | |
---|
Substituents | - Prostaglandin skeleton
- Long-chain fatty acid
- Fatty alcohol
- Hydroxy fatty acid
- Keto fatty acid
- Cyclopentanol
- Cyclic alcohol
- Secondary alcohol
- Ketone
- Carboxylic acid derivative
- Carboxylic acid
- Monocarboxylic acid or derivatives
- Organic oxide
- Organic oxygen compound
- Alcohol
- Hydrocarbon derivative
- Organooxygen compound
- Carbonyl group
- Aliphatic homomonocyclic compound
|
---|
Molecular Framework | Aliphatic homomonocyclic compounds |
---|
External Descriptors | |
---|
Biological Properties |
---|
Status | Detected and Not Quantified |
---|
Origin | Not Available |
---|
Cellular Locations | Not Available |
---|
Biofluid Locations | Not Available |
---|
Tissue Locations | Not Available |
---|
Pathways | Not Available |
---|
Applications | Not Available |
---|
Biological Roles | Not Available |
---|
Chemical Roles | Not Available |
---|
Physical Properties |
---|
State | Not Available |
---|
Appearance | Not Available |
---|
Experimental Properties | Property | Value |
---|
Melting Point | Not Available | Boiling Point | Not Available | Solubility | Not Available |
|
---|
Predicted Properties | |
---|
Spectra |
---|
Spectra | Spectrum Type | Description | Splash Key | View |
---|
GC-MS | GC-MS Spectrum - GC-MS (1 MEOX; 4 TMS) | splash10-0fj0-4920000000-106328b50f1f2f297ec4 | Spectrum | GC-MS | GC-MS Spectrum - GC-MS (Non-derivatized) | splash10-0fj0-4920000000-106328b50f1f2f297ec4 | Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - GC-MS (Non-derivatized) - 70eV, Positive | splash10-0fbc-7889000000-c51e44d63bd792b1ec6d | Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - GC-MS (4 TMS) - 70eV, Positive | splash10-0006-4100279000-1636439cbaa3cd775a98 | Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - GC-MS (Non-derivatized) - 70eV, Positive | Not Available | Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 10V, Positive | splash10-0f79-0019000000-cc7bcdd01a8e316b6f16 | Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 20V, Positive | splash10-000i-3269000000-48cfefe23c0a5753c60b | Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 40V, Positive | splash10-0596-9451000000-dd83fb4bf88cd772a8c1 | Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 10V, Negative | splash10-0gb9-0019000000-93edc1e964871bcde0a3 | Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 20V, Negative | splash10-0pvi-2289000000-3e28055c2f4d8dfcd540 | Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 40V, Negative | splash10-0a4i-9431000000-747a8063fb8f9cdcc3c9 | Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 10V, Positive | splash10-0f79-0019000000-704513759e9fd1ad8e9b | Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 20V, Positive | splash10-052r-9366000000-7750caf5dc0451a37f06 | Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 40V, Positive | splash10-0a4l-9400000000-21328656b96a98f4c9f8 | Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 10V, Negative | splash10-0gc0-0009000000-b634e12e6a20562bd35f | Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 20V, Negative | splash10-1030-0297000000-896903bc299e1df75493 | Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 40V, Negative | splash10-0a6r-9640000000-b2f2f57806964f492154 | Spectrum |
|
---|
Toxicity Profile |
---|
Route of Exposure | Not Available |
---|
Mechanism of Toxicity | Not Available |
---|
Metabolism | Not Available |
---|
Toxicity Values | Not Available |
---|
Lethal Dose | Not Available |
---|
Carcinogenicity (IARC Classification) | Not Available |
---|
Uses/Sources | Not Available |
---|
Minimum Risk Level | Not Available |
---|
Health Effects | Not Available |
---|
Symptoms | Not Available |
---|
Treatment | Not Available |
---|
Concentrations |
---|
| Not Available |
---|
External Links |
---|
DrugBank ID | Not Available |
---|
HMDB ID | HMDB0002886 |
---|
FooDB ID | FDB023077 |
---|
Phenol Explorer ID | Not Available |
---|
KNApSAcK ID | Not Available |
---|
BiGG ID | Not Available |
---|
BioCyc ID | Not Available |
---|
METLIN ID | 6782 |
---|
PDB ID | Not Available |
---|
Wikipedia Link | Not Available |
---|
Chemspider ID | 4444411 |
---|
ChEBI ID | 28158 |
---|
PubChem Compound ID | 5280888 |
---|
Kegg Compound ID | C05961 |
---|
YMDB ID | Not Available |
---|
ECMDB ID | Not Available |
---|
References |
---|
Synthesis Reference | Not Available |
---|
MSDS | Not Available |
---|
General References | 1. https://www.ncbi.nlm.nih.gov/pubmed/?term=11034952 | 2. https://www.ncbi.nlm.nih.gov/pubmed/?term=11481608 | 3. https://www.ncbi.nlm.nih.gov/pubmed/?term=11510754 | 4. https://www.ncbi.nlm.nih.gov/pubmed/?term=11529335 | 5. https://www.ncbi.nlm.nih.gov/pubmed/?term=11798014 | 6. https://www.ncbi.nlm.nih.gov/pubmed/?term=12535846 | 7. https://www.ncbi.nlm.nih.gov/pubmed/?term=12912853 | 8. https://www.ncbi.nlm.nih.gov/pubmed/?term=14735492 | 9. https://www.ncbi.nlm.nih.gov/pubmed/?term=15108967 | 10. https://www.ncbi.nlm.nih.gov/pubmed/?term=15550787 | 11. https://www.ncbi.nlm.nih.gov/pubmed/?term=15684771 | 12. https://www.ncbi.nlm.nih.gov/pubmed/?term=15883739 | 13. https://www.ncbi.nlm.nih.gov/pubmed/?term=18942642 | 14. https://www.ncbi.nlm.nih.gov/pubmed/?term=6107345 | 15. https://www.ncbi.nlm.nih.gov/pubmed/?term=6132981 | 16. https://www.ncbi.nlm.nih.gov/pubmed/?term=7864124 | 17. https://www.ncbi.nlm.nih.gov/pubmed/?term=9013819 | 18. de la Cruz JP, Guerrero A, Gonzalez-Correa JA, Marquez E, Nacle I, Sanchez de la Cuesta F: Effects of two preparations of 75-mg extended-release aspirin on platelet aggregation, prostanoids and nitric oxide production in humans. Eur J Clin Pharmacol. 2002 Jan;57(11):775-80. | 19. Laitinen O, Seppala E, Nissila M, Vapaatalo H: Plasma levels and urinary excretion of prostaglandins in patients with rheumatoid arthritis. Clin Rheumatol. 1983 Dec;2(4):401-6. | 20. Jawerbaum A, Rosello Catafau J, Gonzalez ET, Novaro V, Gomez G, Gelpi E, Gimeno MA: Eicosanoid production by placental and amnion tissues from control and non-insulin-dependent diabetic rats. Influence of oxytocin in the incubating medium. Prostaglandins Leukot Essent Fatty Acids. 1997 Jun;56(6):425-9. | 21. Cerletti C, Dell'Elba G, Manarini S, Pecce R, Di Castelnuovo A, Scorpiglione N, Feliziani V, de Gaetano G: Pharmacokinetic and pharmacodynamic differences between two low dosages of aspirin may affect therapeutic outcomes. Clin Pharmacokinet. 2003;42(12):1059-70. | 22. Katori M, Majima M, Harada Y: Possible background mechanisms of the effectiveness of cyclooxygenase-2 inhibitors in the treatment of rheumatoid arthritis. Inflamm Res. 1998 Oct;47 Suppl 2:S107-11. | 23. Fain JN, Ballou LR, Bahouth SW: Obesity is induced in mice heterozygous for cyclooxygenase-2. Prostaglandins Other Lipid Mediat. 2001 Jul;65(4):199-209. | 24. Rogov VA, Shilov EM, Kozlovskaia NL, Gordovskaia NB, Sidorova IS, Krylova MIu, Artem'eva VB: [Endothelium and platelets in pregnant women with chronic glomerulonephritis and therapeutic efficacy of acetylsalicylic acid and dipiridamol]. Ter Arkh. 2004;76(12):58-64. | 25. Wubert J, Reder E, Kaser A, Weber PC, Lorenz RL: Simultaneous solid phase extraction, derivatization, and gas chromatographic mass spectrometric quantification of thromboxane and prostacyclin metabolites, prostaglandins, and isoprostanes in urine. Anal Chem. 1997 Jun 1;69(11):2143-6. | 26. Wang GQ, Zou ZZ, Yu DP: [A study of the role of plasma thromboxane B2 and 6-keto-prostaglandin F1 alpha in epidemic hemorrhagic fever]. Zhonghua Nei Ke Za Zhi. 1990 Mar;29(3):138-40, 188. | 27. Terada K, Hayashi G, Hokama Y: C-reactive protein and 6-keto prostaglandin F 1-alpha in patients with gynecologic cancer. Gynecol Oncol. 1990 Feb;36(2):212-4. | 28. Miao XY: [Plasma level and effects of thromboxane A2 and 6-keto-PGF1 alpha in patients with acute obstructive suppurative cholangitis]. Zhonghua Wai Ke Za Zhi. 1990 Apr;28(4):228-30, 253-4. | 29. Symons JD: Longitudinal and cross-sectional studies of the relationship between 6-keto PGF1 alpha and high density lipoproteins. Prostaglandins Leukot Essent Fatty Acids. 1990 Feb;39(2):159-65. |
|
---|